Table 1.
Characteristics at baseline in COVID-19 patients with and without re-positive to 2019-nCoV nucleic test
| Total (n = 126) | Re-positive (n = 3) | Non-re-positive (n = 123) | |
|---|---|---|---|
| Age (years), median (IQR) | 66 (54–69) | 71 (60–76) | 62 (53–69) |
| Male, n (%) | 61 (48.4) | 1 (33.3) | 60 (48.8) |
| Current smoker, n (%) | 13 (10.3) | 0 (0) | 13 (10.6) |
| Often drinker, n (%) | 3 (2.4) | 0 (0) | 3 (2.4) |
| Hypertension, n (%) | 39 (31.0) | 1 (33.3) | 38 (30.9) |
| Diabetes, n (%) | 26 (20.6) | 1 (33.3) | 25 (20.3) |
| COPD, n (%) | 5 (4.0) | 1 (33.3) | 4 (3.3) |
| CHD, n (%) | 16 (12.7) | 0 (0) | 16 (13.0) |
| Digestive disease, n (%) | 13 (10.3) | 1 (33.3) | 12 (9.8) |
| Previous tumor, n (%) | 8 (6.3) | 0 (0) | 8 (6.5) |
| Immunosuppressive drugs, n (%) | 2 (1.6) | 0 (0) | 2 (1.6) |
| Renal impairment, n (%) | 16 (12.7) | 1 (33.3) | 15 (12.2) |
| Wet market exposure, n (%) | 1 (0.8) | 0 (0) | 1 (0.8) |
| Clinical manifestation | |||
| Fever, n (%) | 87 (69.0) | 2 (66.7) | 85 (69.1) |
| Dry cough, n (%) | 75 (59.5) | 2 (66.7) | 73 (59.3) |
| Productive cough, n (%) | 18 (14.3) | 0 (0) | 18 (14.6) |
| Fatigue, n (%) | 49 (38.9) | 0 (0) | 49 (39.8) |
| Muscle or joint ache, n (%) | 16 (12.7) | 0 (0) | 16 (13.0) |
| Thoracalgia, n (%) | 26 (20.6) | 1 (33.3) | 25 (20.3) |
| Sore throat, n (%) | 17 (13.5) | 0 (0) | 17 (13.8) |
| Diarrhea, n (%) | 11 (8.7) | 1 (33.3) | 10 (8.1) |
| Catarrh, n (%) | 4 (3.2) | 0 (0) | 4 (3.3) |
| Anorexia, n (%) | 41 (32.5) | 0 (0) | 41 (33.3) |
| Shortness of breath, n (%) | 49 (38.9) | 1 (33.3) | 48 (39.0) |
| Headache, n (%) | 15 (11.9) | 1 (33.3) | 14 (11.4) |
| Total symptoms (IQR) | 3 (2–4) | 3 (2–4) | 3 (2–4) |
| Routine blood examinations | |||
| Decreased leukocytes, n (%) | 8 (6.3) | 1 (33.3) | 7 (5.7) |
| Decreased lymphocytes, n (%) | 39 (31.0) | 1 (33.3) | 38 (30.9) |
| Decreased hemoglobin, n (%) | 31 (24.6) | 2 (66.7) | 29 (23.6) |
| Decreased platelets, n (%) | 9 (7.1) | 1 (33.3) | 8 (6.5) |
| ALT > 40 U/L | 37 (29.4) | 0 | 37 (30.1) |
| AST > 40 U/L | 25 (19.8) | 0 | 25 (20.3) |
| Albumin <30 g/L | 7 (5.7) | 0 | 7 (5.7) |
| LDH > 245 g/L | 39 (31.0) | 2 (66.7) | 37 (30.1) |
| CRP > 4 mg/L (data available in 125 patients) | 65 (52.0) | 2 (100) | 63 (51.2) |
| CT findings, n (%) | |||
| Unilateral pneumonia, n (%) | 18 (14.3) | 1 (33.3) | 17 (13.8) |
| Bilateral pneumonia, n (%) | 73 (57.9) | 1 (33.3) | 72 (58.5) |
| Multiple mottling and ground-glass opacity, n (%) | 35 (27.8) | 1 (33.3) | 34 (27.6) |
| Treated with steroid, n (%) | 12 (9.5) | 0 | 12 (9.8) |
| Antiviral, n (%) | 123 (97.6) | 3 (100) | 120 (97.6) |
| Treated with CTM, n (%) | 121 (96.0) | 3 (100) | 118 (95.9) |
| Antibacterial, n (%) | 97 (72.4) | 2 (66.7) | 95 (72.5) |
| Severe COVID-19, n (%) | 13 (10.6) | 1(33.3) | 14 (11.1) |
| Onset to admission (day), median (IQR) | 13 (7–20) | 10 (9–12) | 13 (8–20) |
| Hospital stay (day), median (IQR) | 26 (18–33) | 26 (19–31) | 26 (18–33) |
Decreased means below the lower limit of the normal range. Leukocytes (× 109/L; normal range 3.5–9.5); lymphocytes (× 109/L; normal range 1.1–3.2); platelets (× 109 /L; normal range 125–350); hemoglobin (g/L; normal range 130–175); ALT and AST (U/L; normal range 0–40); LDH (U/L; normal range 109–245); CRP (mg/L; normal range < 4.0)
IQR, interquartile range; COVID-19, coronavirus disease 2019; COPD, chronic obstructive pulmonary disease; CHD, coronary heart disease; ALT, alanine transaminase; AST, alanine aminotransferase; LDH, lactate dehydrogenase; CRP, C-reactive protein; CT, computed tomography; CTM, Chines traditional medicine